Mark McKenna
Board Member
Spyre Therapeutics, Inc. (SYRE)Equibles does not estimate personal net worth.
Get an email with a short summary when Spyre Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SYRE alertsAbout Mark McKenna
Mark McKenna is recorded as Board Member at Spyre Therapeutics, Inc. (SYRE). The newest filing on record that lists Mark McKenna as Board Member at Spyre Therapeutics, Inc. (SYRE) is dated April 10, 2026. Spyre Therapeutics, Inc. reported in an 8-K filed May 29, 2026 that Mark McKenna was appointed Class I director, effective May 27, 2026. Spyre Therapeutics, Inc. reported in an 8-K filed February 5, 2024 that Mark McKenna was appointed Class I director, effective February 1, 2024. Spyre Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Spyre Therapeutics, Inc. includes Cameron Turtle (CEO, COO and Board Member), Cameron Turtle, DPhil (CEO and Board Member), James Kastenmayer (CEO) and 7 others.
“The Company’s stockholders elected three Class I directors, Mark McKenna, Cameron Turtle, and Laurie Stelzer, each to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.”
“On February 1, 2024, the Board appointed Mark McKenna as a Class I director to fill the vacancy resulting from Ms. Lawton's resignation, effective immediately.”
Affiliation history
-
Current
Start not stated–present
Last confirmed April 10, 2026
Company network
Leadership on record at Spyre Therapeutics, Inc.
- Cameron Turtle CEO, COO, Board Member
- Cameron Turtle, DPhil CEO, Board Member
- James Kastenmayer CEO
- Jeffrey M. Goldberg CEO
- Scott Burrows CFO, Chief Accounting Officer
- Heidy Abreu King-Jones General Counsel
- Jonathan Alspaugh Chief Accounting Officer
- Steven Weber Chief Accounting Officer
- Jeffrey Albers Board Member
- Laurie Stelzer Board Member